Clinical impact of Ocrelizumab extended interval dosing during the COVID-19 pandemic and associations with CD19(+)B-cell repopulation

por Sahi, Nitin Kumar, Abidi, Syed Muhammad Ali, Salim, Omar, Abraham, Roby, Kalra, Seema, Al-Araji, Adnan
Publicado 2021